Sustanon 250 250mg/ml 1x1ml Ampullen by Aspen

Usage

1. Review the compound's documented history and pharmacokinetic profile (Nieschlag et al., 1976) to understand the expected onset and duration curve from each of the four esters before planning your injection schedule.
2. Inspect the 1 ml glass ampoule for visible particles or discolouration; the solution should be clear to slightly yellow — consistent with arachis oil carrier, unchanged from the original Organon formulation.
3. Snap the ampoule open using a sterile gauze wrap at the score mark; draw the full 1 ml into a sterile syringe using a filter needle (18–21G) to prevent glass particle contamination.
4. Switch to a fresh injection needle (21–23G, 1–1.5 inch) appropriate for intramuscular administration into the gluteus medius, vastus lateralis, or deltoid — sites used in original clinical trials.
5. Administer slowly over 30–60 seconds to minimise post-injection discomfort associated with the arachis oil vehicle; aspirate briefly prior to injection as standard IM practice.
6. Dispose of the opened single-dose ampoule immediately after use — the single-dose format means no residual solution should be stored; log injection site and date for protocol tracking.

Warnings

Frequently asked questions

Where did Sustanon 250 originally come from and who developed it?

Sustanon 250 was originally developed by Organon Laboratories, a Dutch pharmaceutical company, in the early 1970s. The formulation was designed in the Netherlands to address practical limitations of existing testosterone therapies, combining four esters of different chain lengths into one preparation. It was subsequently licensed and marketed across Europe and became one of the most widely prescribed testosterone replacement products in medical history.

When was Sustanon 250 first approved and what was its original clinical purpose?

Sustanon 250 received its first regulatory approvals in European markets during the 1970s, with its primary clinical indication being male hypogonadism — a condition where the testes produce insufficient testosterone. Its multi-ester design was intended to reduce injection frequency while maintaining physiological testosterone levels, making it significantly more practical for long-term hormone replacement compared to single-ester formulations available at the time.

How has the use of Sustanon 250 evolved from its original medical purpose to modern applications?

Initially, Sustanon 250 was used exclusively in endocrinology clinics for hypogonadism treatment. Through the 1980s and 1990s, its sustained-release profile attracted interest in sports medicine and, later, performance-enhancement contexts. Today, Aspen continues manufacturing it for legitimate therapeutic use under GMP EU Annex 1 standards, while its pharmacokinetic profile — documented since Nieschlag et al. (1976) — remains a reference point in testosterone replacement literature.

Why is the single-dose 1 ml ampoule format preferred over multi-dose vials for Sustanon 250?

Single-dose ampoules eliminate the risk of contamination and preservative accumulation associated with multi-dose vials. Each 1 ml Aspen ampoule is sealed under sterile conditions, ensuring the compound's integrity from manufacture to administration. This format is particularly relevant for the benzyl-alcohol-preserved arachis oil carrier used in Sustanon 250, as repeated puncture of a shared vial increases bacterial ingress risk over time.

Is Sustanon 250 at 250 mg/ml considered a low, standard, or high concentration among testosterone blends?

At 250 mg/ml, Sustanon 250 sits at the entry-level end of injectable testosterone blend concentrations, making it one of the more accessible concentrations for individuals beginning hormone replacement therapy or anabolic protocols. Higher-concentration blends such as 300 mg/ml or 400 mg/ml formulations exist, but 250 mg/ml remains the original and most clinically studied concentration, offering predictable pharmacokinetics backed by decades of documented use. (2) angle_used

Manufacturer

Aspen Pharmacare was founded in 1997 in Port Elizabeth, South Africa, by Stephen Saad and Gus Attridge, making it one of the youngest companies to scale to global pharmaceutical significance in under three decades. Beginning as a generics-focused distributor in sub-Saharan Africa, Aspen executed a series of strategic acquisitions — most notably the 2013 purchase of Merck's branded thrombosis and anaesthesia product portfolios in Europe, and the subsequent acquisition of AstraZeneca's anaesthetic brands — that transformed it into a manufacturer with GMP-certified sterile injectables capacity across facilities in the Netherlands (Oss), South Africa, and Australia. Its Sustanon 250 supply in European markets is produced under EU GMP Annex 1 sterile manufacturing regulations, with batch documentation, HPLC analytical release testing, and LAL endotoxin compliance required before any unit enters distribution. Aspen is listed on the Johannesburg Stock Exchange (JSE: APN) and operates in over 150 countries, with revenues exceeding ZAR 36 billion (FY2023 annual report), reflecting a brand trajectory from regional generic distributor to globally Established Brand in specialty injectable pharmaceuticals.